Heptares Therapeutics Limited

Nxera Pharma UK Limited

Other

Allergan Pharmaceuticals International Limited

Benjamin Gerald Tehan

Miles Stuart Congreve

Giles Albert Brown

Mark Pickworth

Julie Elaine Cansfield

Barry John Teobald

John Andrew Christopher

Sarah Joanne Aves

Mark David Rackham

Michael Alistair O'Brien

Sukhbinder Singh Klair

Shawn Donald Johnstone

Sarah Joanne Bucknell

Karl Henrik Edman

Mark Mills

Nigel Alan Swain

Anil Patel

Dean Gordon Brown

Anne Mary Stephenson

John Graham Cumming

Frank Xinhe Wu

Hongming Chen

Roland Werner Burli

Geraint Jones

Andrew William Phillips

Michael Alistair O'brien

Barry John Teobold

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rand n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Orexin 1 receptor antagonists

This invention relates to compounds that are agonists of the muscarinic Mand/or Mreceptor and which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X; X; Y; R; R; R; R; Rand Rare as defined herein.

Oxime compounds as agonists of the muscarinic Mand/or Mreceptor

The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Oxexin 1 receptor antagonists

This invention related to compounds having activity as muscarinic Mor Mand Mreceptor agonists which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where X; X; X; X; Y; Z; n, Rand Rare defined herein.

Quinolinone and benzoxazine derivatives as muscarinic Mand/or Mreceptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor and which are useful in the treatment of muscarinic Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X, X, R, R, Rand Rare as defined herein.

Muscarinic receptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or Mreceptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R, R, R, Rand Rare as defined herein.

Muscarinic agonists

This invention relates to compounds that are agonists of the muscarinic Mand/or Mreceptor and which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X; X; Rand Rare as defined herein.

Bicyclic aza compounds as muscarinic Mand/or Mreceptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor or Mand Mreceptors and which are useful in the treatment of muscarinic Mor M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q, Q, R, p, V, Q, Q, X, Xand W are defined herein.

Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R-Rare as defined herein.

Muscarinic M1 receptor agonists

This invention relates to compounds that are agonists of the muscarinic Mand/or Mreceptor and which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where Y, R, Rand Rare as defined herein.

Pharmaceutical compounds

Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

This invention relates to compounds that are agonists of the muscarinic Mand/or Mreceptor and which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1) wherein X; X; Rand Rare as defined herein.

This invention relates to compounds that are agonists of the muscarinic Mreceptor and/or Mreceptor and which are useful in the treatment of muscarinic M/Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1a or a salt thereof, wherein n, p, Q, R, R, R, Rand Rare as defined herein.

Growing community of inventors

Cambridge, United Kingdom

Benjamin Gerald Tehan